Frank Mottola - Feb 22, 2022 Form 4/A - Amendment Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: SVP, Quality, GMP, Ops, IT
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Stock symbol: SUPN
Transactions as of: Feb 22, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 2/25/2022, 04:15 PM
Date Of Original Report: Feb 24, 2022
Next filing: Jan 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SUPN	Common Stock						7.44K	Feb 22, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Employee Stock Option (Right to Buy)	Award	$0	+18K		$0.00	18K	Feb 22, 2022	Common Stock	18K	$32.20	Direct	F3
transaction	SUPN	Restricted Stock Units	Award	$0	+3K		$0.00	3K	Feb 22, 2022	Common Stock	3K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an aggregate of 605 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
F2	The option vests in four equal annual installments beginning on February 22, 2023.
F3	Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F4	The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023.